載入中
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical firm. Its leading investigational drug in clinical development is PEDMARK, a specialized formulation of sodium thiosulfate. This treatment is designed to shield young cancer patients from hearing damage (ototoxicity) that can be induced by platinum-based chemotherapy. The company, which was founded in 1996, previously operated under the name Adherex Technologies Inc. before officially rebranding as Fennec Pharmaceuticals Inc. in September 2014. Its corporate headquarters are situated in Research Triangle Park, North Carolina.
前收盤價
US$10.71
+US$0.08 · +0.75%
盤中時間採用ET。市場資料可能有所延遲。
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical firm. Its leading investigational drug in clinical development is PEDMARK, a specialized formulation of sodium thiosulfate. This treatment is designed to shield young cancer patients from hearing damage (ototoxicity) that can be induced by platinum-based chemotherapy. The company, which was founded in 1996, previously operated under the name Adherex Technologies Inc. before officially rebranding as Fennec Pharmaceuticals Inc. in September 2014. Its corporate headquarters are situated in Research Triangle Park, North Carolina.
日內區間
目前US$10.71
52週區間
目前US$10.71
盤中時間採用ET。市場資料可能有所延遲。
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical firm. Its leading investigational drug in clinical development is PEDMARK, a specialized formulation of sodium thiosulfate. This treatment is designed to shield young cancer patients from hearing damage (ototoxicity) that can be induced by platinum-based chemotherapy. The company, which was founded in 1996, previously operated under the name Adherex Technologies Inc. before officially rebranding as Fennec Pharmaceuticals Inc. in September 2014. Its corporate headquarters are situated in Research Triangle Park, North Carolina.
日內區間
目前US$10.71
52週區間
目前US$10.71
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 4464.2萬 USD | 4753.8萬 USD | 2125.2萬 USD | 153.5萬 USD | — |
| 銷貨成本 | 376.4萬 USD | 318.4萬 USD | 125.9萬 USD | 8.6萬 USD | — |
| 毛利 | 4087.8萬 USD | 4435.4萬 USD | 1999.3萬 USD | 144.9萬 USD | — |
| 研究與開發 | 25萬 USD | 30.7萬 USD | 5.6萬 USD | 353.1萬 USD | 498.1萬 USD |
| 銷售、一般及管理費用 | 4691萬 USD | 4147.9萬 USD | 3270.8萬 USD | 2050.7萬 USD | 1224.2萬 USD |
| 營業費用 | 4722.4萬 USD | 4187.5萬 USD | 3305.1萬 USD | 2418.7萬 USD | 1722.3萬 USD |
| 利息收入 | 78.7萬 USD | 159.3萬 USD | 44.1萬 USD | 19.5萬 USD | 5.4萬 USD |
| 利息支出 | 208萬 USD | 406.9萬 USD | 339.4萬 USD | 97.8萬 USD | 12.6萬 USD |
| 折舊和攤銷 | 10.3萬 USD | 80萬 USD | 28.7萬 USD | 14.9萬 USD | 1.6萬 USD |
| 營業利益 | −634.6萬 USD | 247.9萬 USD | −1305.8萬 USD | −2273.8萬 USD | −1722.3萬 USD |
| 淨利 | −974.1萬 USD | −43.6萬 USD | −1604.5萬 USD | −2371.4萬 USD | −1734.6萬 USD |
公司資料更新於 2026年10月11日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI1006.76萬0.00%2.3兆 USD0.03%US$381.94+0.63%
iShares Russell 2000 ETFIWM818.44萬0.01%787.4億 USD0.19%US$278.94+0.49%
iShares Russell 2000 Growth ETFIWO288.76萬0.02%139.17億 USD0.24%US$356.78+0.94%
Vanguard Russell 2000 ETFVTWO205.68萬0.01%180億 USD0.06%US$112.66+0.50%
iShares Micro-Cap ETFIWC96.64萬0.07%13.17億 USD0.60%US$183+0.11%
Vanguard Russell 2000 Growth ETFVTWG39.49萬0.02%17億 USD0.06%US$260.49+0.91%
iShares Russell 2500 ETFSMMD17.21萬0.00%40.62億 USD0.23%US$86.29+0.38%
Global X - Russell 2000 ETFRSSL14.76萬0.01%14.19億 USD0.08%US$109.09+0.21%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOiShares Micro-Cap ETFIWCVanguard Russell 2000 Growth ETFVTWGiShares Russell 2500 ETFSMMDGlobal X - Russell 2000 ETFRSSLAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
